Solution for inhalation pharmaceutical composition glucovance and the method of its therapeutic applications

 

Solution for inhalation contains, by weight. %: Glutoxim 1,90-2,10 representing bis-(gamma-L-glutamyl)-L-cystinyl-bis-glycine disodium salt, theophylline 0,45-0,55, Riboxin 0,90-1,10, dimexide 2,80-3,20, sodium chloride 0.75 to 0.95, and the rest is water for injection to 10, the Solution based on Glutoxim provides a dispersion of microparticles in the range of 5-10 μm inhalation via nebulizer with compressor compressed air (oxygen) and has cytoprotective, immunomodulatory, bronchodilators, desensitizing, anti-microbial and anti-inflammatory activity. Also proposes a method for the prevention and treatment of chronic diseases of the lower respiratory tract viral and bacterial origins by introducing the patient to the specified solution. 2 C. and 7 C. p. F.-ly, 3 tables.

Tablicy

Claims

1. Dosage form of the pharmaceutical composition on the basis of drug Glutoxim representing bis-(gamma-L-glutamyl)-L-cystinyl-bis-glycine disodium salt that contains sodium chloride and water, characterized in that it is a solution for inhalation, optionally containing theophylline, Riboxin, dimexide the next time with the/p>Sodium chloride 0,75-0,95

The rest is Water for injection to 10 g

2. Dosage form of the pharmaceutical composition under item 1, characterized in that it provides a dispersion of microparticles in the range of 5-10 μm inhalation via nebulizer with compressor compressed air (oxygen).

3. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it has a system cytoprotective activity.

4. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it has immunomodulatory activity.

5. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it possesses bronchodilatory activity.

6. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it has a desensitizing activity.

7. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it possesses antimicrobial activity.

8. Dosage form of the pharmaceutical composition under item 1 or 2, characterized in that it has anti-inflammatory activity.

9. Method for the treatment and prevention of acute respiratory infections and chronic infectious Ospanova funds via nebulizer using ultrasound or compressor compressed air, characterized in that the medicinal product is administered dosage form of the pharmaceutical composition described in any of paragraphs.1-8, in the region of the terminal bronchioles and alveoli at least once a day during the time required to achieve therapeutic effect.

 

Same patents:

The invention relates to derivatives of 2-(arylvinyl)aminoimidazole formula I, where R1denotes a group of formula (A), (B) or (C), a R2, R3, R4, R5, R6and X are such as defined in the claims

The invention relates to medicine and can be used in the practice of Spa and medical institutions

The invention relates to N-oxides of heterocyclic compounds of the formula (I), where R1is CH3CH2F, CHF2, CF3; R2is CH3, CF3; R3represents F, Cl, Br, CH3; R4represents H, F, Cl, Br, CH3

The invention relates to a method for producing a pharmaceutical composition for the treatment of painful conditions, mediated by leukotriene antagonists, pharmaceutical compositions for the treatment of painful conditions, mediated by leukotriene antagonists, containing a number of balls containing amorphous zafirlukast, and also to a method of treatment of the above disease conditions
The invention relates to medicine and can be used in pulmonology in the treatment of aspirin-induced asthma

The invention relates to new phosphorylated derivative of phenylacetic acid of the formula (II), where R1means-CH2THE OP(O)(OH)2and R2means HE; R1means-CH3and R2means-OP(O)(OH)2

Arylalkylamine // 2201923
The invention relates to arylalkylamines formula I, where B - A, OA, NH2, CF3, aromatic heterocycle selected from pyridine, pyrazine and pyrimidine; Q is absent or denotes alkylene with 1-6 carbon atoms; R1and R2independently from each other represent OR5where R5- Or cycloalkyl with 3-7 carbon atoms; And the alkyl with 1-10 carbon atoms, and their physiologically acceptable salts

The invention relates to new derivatives of substituted phenyl of the formula (1) or their pharmaceutically acceptable salts, hydrates or N-oxides, where R is a C1-C6-alkyl, halogen - C1-C6alkyl or C3-C8cycloalkyl; Randis hydrogen, C1-C6alkyl or halogen - C1-C6alkyl; Z represents a group-CHR4-CH2R5(A) or-CR4=CHR5(In); where R4is hydrogen or the group -(CH2)tAr or (CH2)tAr(Alk4)r(O)s(Alk5)t, Ar', where Ar and Ar' is phenyl, optionally substituted with substituents selected from the group comprising FROM1-C6alkyl, CF3, NO2, NH2WITH1-C6alkylcarboxylic,1-C6alkylsulfonamides and di(C1-C6alkyl)aminosulfonyl; Alk4and Alk5- C1-C6alkylene group, optionally substituted with halogen or hydroxy-group; t = 0 or an integer 1, 2 or 3; r, s and t''= 0 or 1, R5represents pyridyl, optionally substituted phenyl WITH1-C6the alkyl

The invention relates to new carboxyterminal cyclic carboxamide derivative of formula 1

< / BR>
where G1- CH2; G2- C(O); m = 2 or 3, n is 0 or 1; R1is 1-3 substituent, independently selected from H, G, C1-C6alkoxy; R2is 1-3 substituent, independently selected from H, C1-C6alkoxy; R3means N or

< / BR>
< / BR>
< / BR>
R4- H; Ar1means

< / BR>
< / BR>
R8means 1-3 substituent, independently selected from H, G; R9means N;

And means

< / BR>
< / BR>
< / BR>
where p = 1, 2, 3, or 4; X is-O-, -CH2-; R10-H, C1-C6alkyl or

< / BR>
">< / BR>
< / BR>
< / BR>
where q = 2 or 3; R5- C1-C4alkyl, (CH2)2HE; R6- C1-C4alkyl, -(CH2)2HE, (CH2)2N(CH3)2; R5', R6' - C1-C4alkyl; R7- C1-C6alkyl, and the stereoisomers and pharmaceutically acceptable salts

The invention relates to the field of medicine and for the prevention and treatment of infectious and inflammatory diseases of the oral cavity and pharynx

The invention relates to biotechnology and medicine and can be used to obtain variation Gnkazy I person with reduced affinity binding against actin

The invention relates to the field of veterinary pharmacology and chemotherapy
The invention relates to medicine

The invention relates to the field of medicine and for the application of hydrogenated soy phosphatidylcholine (Phospholipon-N) as an active ingredient, providing a surface-active properties of drugs for substitution of the surfactant therapy

-interleukin" target="_blank">

The invention relates to compounds of General formulaand-

< / BR>
< / BR>
where n = 0, 1, or 2, m and m' = 1 or 2; R11is

< / BR>
or

< / BR>
R2'= R2= H, R3is-CH2Ar or 5-15 membered non-aromatic monocyclic group which may contain from 0 to 2 endocycles nitrogen atoms; R4is a branched (C1-5) alkyl group; R5choose from a group comprising-C(O)R7, -C(O)OR9, -C(O)C(O)R7; R7selected from the group: phenyl, naphthyl, isoquinoline, and phenyl may be substituted with halogen, (C1-6) alkoxy, 1,2-methylenedioxy or - N(H)C(O)(C1-6)-alkyl, R9independently selected from straight line (C1-5) alkyl group, optionally substituted by phenyl; R12and R13independently selected from the group comprising-R7-C(O)-R7and-C(O)-N(H)-R7or R12and R13together form a 4-8-membered saturated cyclic group, f is -interleukin (ICE), method of inhibiting ICE activity, methods of treating or preventing IL-mediated diseases

The invention relates to the field of medicine and for the preparation of Bresolin drops nasal 0.06% and 0.1% for the treatment of diseases of the nose and throat

The invention relates to the field of medicine and for the preparation of Bresolin drops nasal 0.06% and 0.1% for the treatment of diseases of the nose and throat

The invention relates to the field of medicine and is about creating funds on the basis of Bromhexine hydrochloride

The invention relates to derivatives of 2-(arylvinyl)aminoimidazole formula I, where R1denotes a group of formula (A), (B) or (C), a R2, R3, R4, R5, R6and X are such as defined in the claims

The invention relates to the field of applied biotechnology
Up!